These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 1771411)

  • 1. Neutralization of recombinant hirudin: some practical considerations.
    Fareed J; Walenga JM; Hoppensteadt D; Iyer L; Pifarre R
    Semin Thromb Hemost; 1991 Apr; 17(2):137-44. PubMed ID: 1771411
    [No Abstract]   [Full Text] [Related]  

  • 2. Anticoagulant and antithrombotic actions of recombinant hirudin.
    Kaiser B
    Semin Thromb Hemost; 1991 Apr; 17(2):130-6. PubMed ID: 1837615
    [No Abstract]   [Full Text] [Related]  

  • 3. Some objective considerations for the neutralization of the anticoagulant actions of recombinant hirudin.
    Fareed J; Walenga JM; Pifarre R; Hoppensteadt D; Koza M
    Haemostasis; 1991; 21 Suppl 1():64-72. PubMed ID: 1894198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The comeback of hirudin as an antithrombotic agent.
    Markwardt F
    Semin Thromb Hemost; 1991 Apr; 17(2):79-82. PubMed ID: 1771415
    [No Abstract]   [Full Text] [Related]  

  • 5. The direct thrombin inhibitor hirudin.
    Greinacher A; Warkentin TE
    Thromb Haemost; 2008 May; 99(5):819-29. PubMed ID: 18449411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct thrombin inhibition with Rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement.
    Eriksson BI; Kälebo P; Ekman S; Lindbratt S; Kerry R; Close P
    Thromb Haemost; 1994 Aug; 72(2):227-31. PubMed ID: 7831657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Markers of hemostatic system activation during thromboprophylaxis with recombinant hirudin in total hip replacement.
    Cofrancesco E; Cortellaro M; Leonardi P; Corradi A; Ravasi F; Bertocchi F
    Thromb Haemost; 1996 Mar; 75(3):407-11. PubMed ID: 8701398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined administration of barbourin--albumin and hirudin--albumin fusion proteins limits fibrin(ogen) deposition on the rabbit balloon-injured aorta.
    Sheffield WP; Gataiance S; Eltringham-Smith LJ
    Thromb Res; 2007; 119(2):195-207. PubMed ID: 16478628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
    Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
    Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of recombinant hirudin as a therapeutic anticoagulant and antithrombotic agent: some objective considerations.
    Walenga JM; Pifarre R; Hoppensteadt DA; Fareed J
    Semin Thromb Hemost; 1989 Jul; 15(3):316-33. PubMed ID: 2688104
    [No Abstract]   [Full Text] [Related]  

  • 11. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits.
    Agnelli G; Pascucci C; Cosmi B; Nenci GG
    Thromb Haemost; 1990 Apr; 63(2):204-7. PubMed ID: 2363121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction and functional evaluation of hirudin derivatives with low bleeding risk.
    Zhang C; Yu A; Yuan B; Dong C; Yu H; Wang L; Wu C
    Thromb Haemost; 2008 Feb; 99(2):324-30. PubMed ID: 18278181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A long-lasting, plasmin-activatable thrombin inhibitor aids clot lysis in vitro and does not promote bleeding in vivo.
    Sheffield WP; Eltringham-Smith LJ; Gataiance S; Bhakta V
    Thromb Haemost; 2009 May; 101(5):867-77. PubMed ID: 19404540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombin effects of native and recombinant hirudins.
    Markwardt F; Stürzebecher J; Glusa E
    Biomed Biochim Acta; 1990; 49(5):399-404. PubMed ID: 2271010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hirudin versus heparin and low-molecular-weight heparin: and the winner is..
    Hull RD; Pineo GF; Raskob GE
    J Lab Clin Med; 1998 Sep; 132(3):171-4. PubMed ID: 9735921
    [No Abstract]   [Full Text] [Related]  

  • 16. Factor VIII and DDAVP reverse the effect of recombinant desulphatohirudin (CGP 39393) on bleeding in the rat.
    Butler KD; Dolan SL; Talbot MD; Wallis RB
    Blood Coagul Fibrinolysis; 1993 Jun; 4(3):459-64. PubMed ID: 8329573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological relevance of anti-recombinant hirudin antibodies--results from in vitro and in vivo studies.
    Liebe V; Brückmann M; Fischer KG; Haase KK; Borggrefe M; Huhle G
    Semin Thromb Hemost; 2002 Oct; 28(5):483-90. PubMed ID: 12420244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of heparin and hirudin on thrombin generation and platelet aggregation after intrinsic activation of platelet rich plasma.
    Gallistl S; Muntean W; Leis HJ
    Thromb Haemost; 1995 Oct; 74(4):1163-8. PubMed ID: 8560429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unstable angina.
    Natarajan M
    Clin Evid; 2002 Dec; (8):225-35. PubMed ID: 12603879
    [No Abstract]   [Full Text] [Related]  

  • 20. Unstable angina.
    Natarajan M
    Clin Evid; 2002 Jun; (7):214-26. PubMed ID: 12230645
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.